Auxilium's Xiaflex in Peyronie's faces 3-month delay, but shares rise
This article was originally published in Scrip
With Auxilium Pharmaceuticals' 28 August disclosure the US FDA had extended by three months its decision date for the supplemental biologics license application (sBLA) for Xiaflex (collagenase clostridium histolyticum) as a treatment for Peyronie's disease – moving the Prescription Drug User Fee Act (PDUFA) action date from 6 September to 6 December – one might think the firm's stock would be adversely impacted.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.